Alpha Tau Medical (NASDAQ:DRTS) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Key Points

• Alpha Tau Medical reported quarterly earnings of ($0.13) EPS, missing analysts' estimates of ($0.12) by ($0.01).
• Despite the earnings miss, Alpha Tau Medical's stock price increased by 5.0%, reaching $3.56 during trading hours.
• HC Wainwright reaffirmed a "buy" rating on the stock with a target price of $9.00.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01), Zacks reports.

Alpha Tau Medical Trading Up 5.0%

Shares of Alpha Tau Medical stock traded up $0.17 during trading hours on Monday, hitting $3.56. The company's stock had a trading volume of 137,525 shares, compared to its average volume of 50,770. The stock has a 50 day moving average of $3.07 and a 200 day moving average of $2.92. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.81 and a quick ratio of 5.81. Alpha Tau Medical has a 12 month low of $2.06 and a 12 month high of $4.39. The company has a market capitalization of $301.96 million, a PE ratio of -7.74 and a beta of 0.99.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "buy" rating and issued a $9.00 target price on shares of Alpha Tau Medical in a research note on Tuesday, April 29th.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.